HSD17B6 Antibodies

17-beta-hydroxysteroid dehydrogenase type 6 (HSD17B6)

NAD-dependent oxidoreductase with broad substrate specificity that reveals both oxidative and reductive activity (in vitro). Has 17-beta-hydroxysteroid dehydrogenase activity towards various steroids (in vitro).

Converts 5-alpha-androstan-3- alpha,17-beta-diol into androsterone and estradiol to estrone (in vitro). Has 3-alpha-hydroxysteroid dehydrogenase activity towards androsterone (in vitro).

Gene Information

Human
Gene Name:	HSD17B6
Uniprot:	O14756
Entrez:	8630

Family

Belongs to:
short-chain dehydrogenases/reductases (SDR) family

Alternative Names

17-beta-HSD 6; 17-beta-HSD6; 17-beta-hydroxysteroid dehydrogenase type 6; 3(alpha->beta)-hydroxysteroid epimerase; 3-alpha->beta-HSE; EC 1.1.1; EC 1.1.1.105; EC 1.1.1.62; EC 1.1.1.63; HSE3-hydroxysteroid epimerase; hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse); hydroxysteroid (17-beta) dehydrogenase 6; NAD+ -dependent 3 alpha-hydroxysteroid dehydrogenase 3-hydroxysteroid epimerase; Oxidative 3-alpha hydroxysteroid dehydrogenase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; oxidoreductase; retinol dehydrogenase; RODH3(alpha->beta)-hydroxysteroid epimerasel; SDR9C6; short

Molecular Weight

Mass (kDA):
35.966 kDA

Genomic Context

Human
Location:	12q13.3
Sequence:	12; NC_000012.12 (56752449..56787790)

Tissue Specificity

Detected in liver and prostate (at protein level). Detected in adult liver, lung, brain, placenta, prostate, adrenal gland, testis, mammary gland, spleen, spinal cord and uterus. Detected in caudate nucleus, and at lower levels in amygdala, corpus callosum, hippocampus, substantia nigra and thalamus. Detected in fetal lung, liver and brain.

Subcellular Localizations

Microsome membrane; Peripheral membrane protein; Lumenal side. Early endosome membrane; Peripheral membrane protein; Lumenal side.

Diseases

• Polycystic Ovary Syndrome
• Insulin Resistance
• Cholangiocarcinoma
• Malignant Neoplasm Of Prostate
• Prostatic Hyperplasia
• Endometrial Polyp
• Benign Prostatic Hypertrophy
• Leg Ulcer
• Ulcer
• Endometriosis, Site Unspecified

• Malignant Neoplasms
• Prostatic Neoplasms
• Varicose Ulcer
• Hyperplasia

Pathways

• Wound Healing
• Menarche
• Localization

PTMs

• Glycoprotein

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/HSD17B6

Boster Bio: Best Uses Of The HSD17B6 Marker

In this article, we'll discuss Boster Bio's Best Uses Of The HSD17B6 High-affinity Marker. We will also talk about identifying cellular targets. Boster antibodies have been validated in Western Blotting, Immunohistochemistry, and ELISA. Boster antibodies have been widely cited in scientific literature and are highly valued by scientists.

Boster Bio

The phenotype of endogenous memory CD8 T cells changes over time and phenotypic heterogeneity decreases with age. Boster's first products for IHC consisted of hundreds of primary antibodies. The company grew to be one of the most important catalog antibody companies in China in the late 1990s. Boster also developed PicoKine(tm), a proprietary ELISA platform which delivers high-sensitivity ELISA products.

Best Uses Of The HSD17B6 Marker

A boster-biomarker is a gene marker that is commonly found in a wide range of cancers. It is particularly useful for tumors with mutations in key proteins. It has the potential to detect and quantify tumor specific protein levels. Additionally, it can also detect drug resistance in certain cancers. Boster scientists can submit results using the HSD17B6 marker for species and applications. Scientists can also receive product credits for their results. These benefits are available for scientists all over the world.

Primary antibodies of high-affinity

Boster Bio, a company that specializes is the development of rabbit monoclonal antibodies (mAbs) with the highest specificity. These primary antibodies are developed using Boster Bio's plasma-cell discovery platform. Boster plasma cells are used to screen cells that have been exposed to proprietary chemistry. This prevents B cells from secreting any antibodies and keeps them on the cell membranes. The resulting clones are used to target diagnostic targets and therapeutic applications.

Boster's high-affinity primary antibodies are ideal for flow cytometry. They have been developed using a proprietary optimization process, which results in high-affinity binding to target proteins with minimal cross-reactivity. Flow cytometry is one of the most commonly used analytical methods in research and development and has a variety of applications in science. To meet the diverse needs of research laboratories, Boster offers a full range of reagents and convenient solutions for PCR.

Secondary antibodies come in two forms: conjugated or unconjugated. The labeling method used will depend on the desired sensitivity and specificity. Common enzymes are horseradish peoxidase, alkalinephosphatase, and horseradish-peroxidase. Horseradish peroxidase is the best choice for immunoassays as it has a greater sensitivity and stability. Anti-peptide antibodies on the other hand have low affinity and contain undigested material. They also contain 15 percent of F(ab)2 fragment.

The production of monoclonal antibodies involves ELISA titration tests. The spleen is taken from the animals that show the highest response to the antibody. These spleen tissues are used to make hybridoma. The selected antibodies undergo further application testing. Boster Bio produces high-affinity monoclonal antibody primary antibodies.

Identifying cellular targets

Recent research revealed that HSD17B6 is associated with higher TNM stages in HCC patients and a higher histological score. Multivariate Cox regression analysis confirmed that this finding was true. HSD17B6 can be used as a biomarker to detect HCC. However, further research is required to determine the true role of this gene in the disease.

It was also determined that HSD17B6 expression is correlated with chemokines. KDR was the most expressed of the six most common chemokines. There were also correlations between the HSD17B6 and CTLA4, LGALS9 and PDCD1, as well as VTCN1.

Different types of immune cells are necessary for the immune response to primary tumor sites. These cells are important in regulating the immune system and influencing tumor progression, therapy and prognosis. HCC patients have a lower number of immune cell infiltrators if HSD17B6 gene expression is inhibited. The gene's expression is also associated with immune cell penetration.

Researchers discovered that this gene encodes a protein that functions both as an oxidoreductase or an epimerase. This protein is involved the in the metabolism androgens such as testosterone. The first association with polycystic breast cancer and polycystic oval syndrome was the polymorphism in HSD17B6. HSD17B6 is associated with tumor growth, metastasis or progression. It is also associated hepatitis.